Oracle stock falls after report reveals thin margins in AI cloud business
CHICAGO - Cosmos Health Inc. (NASDAQ:COSM) announced Friday that its subsidiary SkyPharm S.A. has entered into an exclusive distribution agreement with Diyar United to market and sell its Sky Premium Life nutraceuticals in Kuwait. The company, which has seen its stock surge over 180% in the past six months according to InvestingPro data, continues its international expansion efforts.
The agreement, dated September 28, 2025, grants Diyar United exclusive rights for registration, promotion, logistics, and distribution of Sky Premium Life food supplements in Kuwait. The product line includes formulations such as collagen, vitamins, minerals, and various herbal supplements.
Cosmos Health has received an initial purchase order of over 65,000 units, with additional orders expected as the company builds its sales pipeline in Kuwait.
According to data cited in the company’s press release, Kuwait’s nutritional supplements market was valued at approximately $1.16 billion in 2024 and is projected to reach $1.68 billion by 2030, growing at a compound annual growth rate of around 6.3%.
"This agreement in Kuwait is yet another strong validation of the growing global demand for our Sky Premium Life products," said Greg Siokas, CEO of Cosmos Health, in the press release statement.
Diyar United was described as a distributor with healthcare experience in Kuwait, possessing logistics and regulatory expertise in the local market.
Cosmos Health, a vertically integrated healthcare group, owns several proprietary brands and manufactures pharmaceuticals and supplements through its subsidiary Cana Laboratories S.A., which is licensed under European Good Manufacturing Practices and certified by the European Medicines Agency.
The company currently operates with offices and distribution centers in Greece and the United Kingdom.
In other recent news, Cosmos Health Inc. reported revenue of $28.46 million for the first half of 2025, marking an 11.7% increase compared to the same period in 2024. The company’s gross profit also rose significantly by 53% year-over-year to $3.21 million, highlighting a strategic focus on higher-margin branded products. Shareholders approved an amendment to increase the number of authorized shares to 1.5 billion common stock and 300 million preferred stock, which will take effect following regulatory filing. Cosmos Health has also expanded its operations by launching its Sky Premium Life supplements in the U.S. market, starting with NOOR Collagen. These products are manufactured locally to avoid tariff issues and logistical challenges. Furthermore, the company has begun building an Ethereum treasury with an initial $1 million purchase as part of its digital asset strategy. This move is facilitated through a financing facility of up to $300 million with a U.S.-based institutional investor. Additionally, Cosmos Health’s CEO issued a letter to shareholders detailing the company’s growth strategy and recent achievements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.